CLDX

Celldex TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$46.00

+59.2% vs current

Most likely

Base case

45%

Probability

Target price

$34.00

+17.6% vs current

B-

Bear case

30%

Probability

Target price

$24.00

-17.0% vs current

AI sentiment snapshot

Latest data as of 2026-05-03

AI commentary

This remains a cautious monitoring-style update. Checked primary sources support the April 2, 2026 financing and the February 25, 2026 company update on 2026 readout timing, but the scheduled post-earnings follow-up could not be materially advanced because no company Q1 2026 earnings release or new earnings 8-K was located in the checked SEC/company sources by May 3, 2026. With the anchor price at $32.31 on May 1, 2026 and the deterministic prior still negative, the stock appears to be trading between dilution digestion and waiting for summer/late-2026 clinical proof rather than reacting to a fresh earnings information set.

RankAlpha Sentiment Codex - 2026-05-03

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-15catalystPost-offering cash reset and dilution overhang digestionHigh impact

Celldex disclosed expected net proceeds of about $282 million from its April 1, 2026 equity offering, which materially improves liquidity but leaves the stock needing to absorb dilution and re-anchor around clinical execution rather than financing risk [#8-K-2026-04-02].

2026-08-15eventBarzolvolimab Phase 2 prurigo nodularis toplineHigh impact

Celldex said enrollment is complete in the Phase 2 prurigo nodularis study and topline data are expected in summer 2026, making this one of the nearest clean clinical readouts for the platform [#10-K-2026-02-25].

2026-11-15catalystBarzolvolimab Phase 3 CSU topline path and 2027 BLA setupHigh impact

The February 25, 2026 earnings-linked company update said enrollment in both global Phase 3 CSU studies was completed six months ahead of guidance, with topline data anticipated in Q4 2026 and a planned BLA submission in 2027, making late-2026 execution the main value driver beyond the nearer Phase 2 readouts [#8-K-2026-02-25].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-03 • Updated nightlySource: Internal modelMethodology